Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients

GenWorks Health & Rotary Club partners to transform rural healthcare

GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities

Apollo Hospitals joins MediSage to host Uro-Oncology symposium

Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference

PredOmix, Core Diagnostics partner to launch OncoVeryx-F

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection

Newly patented bone marrow biopsy device to bolster bone cancer treatment in India, says GlobalData

It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone

Johnson & Johnson MedTech India partners with Karkinos to upskill professionals in cancer care

To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022

SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’

Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India